Clinical Study
Utility of Serum Neopterin and Serum IL-2 Receptor Levels to Predict Absolute CD4 T Lymphocyte Count in HIV Infected Cases
Table 1
Demographic and baseline characteristics of the study subjects.
| Characteristic | Group A (CD4 < 200) () | Group B (CD4 200–500) () | Group C (CD4 > 500) () | HIV positive subjects () | Healthy control group () |
| Median (IQR) of age in yrs | 32.0 (25–41) | 32.5 (27–39) | 33.0 (24–39) | 32.5 (24–41) | 31.5 (26–40) | Males/females (No.) | 22/11 | 23/11 | 22/11 | 67/33 | 28/14 | Marital status | | | | | | Married | 23 | 26 | 22 | 71 | 30 | Unmarried | 6 | 5 | 7 | 18 | 9 | Widowed | 4 | 3 | 4 | 11 | 3 | Risk behaviour | | | | | | Heterosexual | 30 | 29 | 27 | 86 | 38 | IVDU* | 2 | 4 | 3 | 9 | 4 | MSM | 1 | 0 | 2 | 3 | 0 | Not known | 0 | 1 | 1 | 2 | 0 | Median (IQR) CD4 count (cells/µL) | 111 (79–154) | 305 (259–392) | 580 (524–750) | 279 (154–482) | 805 (645–1063) | Median (IQR) of S. neopterin (nmol/L) | 38.57 (25.7–126.0) | 22.9 (13.4–40.3) | 16.24 (10.3–23) | 25.5 (15.6–39.7) | 6.3 (4.7–6.8) | Median (IQR) of sIL-2R (pM) | 96.09 (61.4–139.0) | 60.85 (40.8–86.8) | 35.09 (25.2–64.6) | 63 (42.6–100.1) | 4.4 (1.9–8.1) | Mean (range) of PVL (copies/mL) | 145,000 (2436–>750,000) | ND# | ND | 145,000 (2436–>750,000) , group A only | ND |
|
|
Intravenous drug users.
#ND: not done.
|